Skip to main content

Table 1 Patient characteristics

From: Radiographic progression in early rheumatoid arthritis patients following initial combination versus step-up treat-to-target therapy in daily clinical practice: results from the DREAM registry

Characteristics Strategy I (n = 128) Strategy II (n = 128) p
Female, sex n (%) 79 (61.7%) 79 (61.7%) 1.000
Age, mean ± SD years 59.1 ± 13.0 59,5 ± 12.8 0.809
DAS28 - ESR, mean ± SD 4.5 ± 1.1 4.8 ± 1.1 0.026
ESR (mm/h), median (IQR) 22.0 (14.0–41.0) 29.0a (14.0–45.0) 0.195
CRP (mg/l), median (IQR) 10.0b (5.0–22.0) 11.5 (4.3–24.8) 0.786
Anti-CCP positive, n (%) 74c (58.3%) 77c (60.2%) 0.701
RF positive, n (%) 62 (48.4%) 76 (59.4%) 0.114
Number of SJC, median (IQR) 6.0 (3.0–9.0) 5.0 (2.0–10.0) 0.235
Number of TJC, median (IQR) 3.0 (1.0–7.0) 4.0 (2.0–10.0) 0.025
HAQ-SDI, median (IQR) 1.2d (0.9–1.6) 1.0e (0.4–1.5) 0.003
VAS well-being, median (IQR) 50.0 (28.3–65.0) 51.0 (35.0–70.0) 0.290
VAS pain, median (IQR) 50.0f (39.8–64.0) 62.0g (49.0–75.0) 0.001
SF36-PCS, mean ± SD 38.1 ± 7.6h 37.3 ± 9.2i 0.512
SF36-MCS, mean ± SD 40.7 ± 7.4j 44.9 ± 11.9k 0.003
BMI, kg/m2, mean ± SD 26.5 ± 4.8l 26.0 ± 4.1m 0.388
Baseline SHS-score, median (IQR) 3.0 (1.0–7.0)n 2.0 (1.0–5.8)o 0.119
Erosion, median (IQR) 0.0 (0.0–1.0)n 0.0 (0.0–1.0)o 0.012
Joint space narrowing, median (IQR) 2.0 (0.0–5.0)n 1.0 (0.0–1.0)o 0.586
Injection triamcinolone, n% 4 (3.1%) 67 (52.3%) 0.000
  1. a(n = 127), b(n = 121), c(n = 127), d(n = 102), e(n = 87), f(n = 122), g(72), h(n = 105), i(n = 86), j(n = 105), k(n = 86),l(n = 126), m(n = 119), n(n = 126), o(n = 124)
  2. DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, TJC tender joint count, SJC swollen joint count, HAQ-SDI Health Assessment Questionnaire disability index (standard scoring), SF-36 Short-Form 36 health survey (version 2), PCS physical component summary, MCS mental component summary, BMI body mass index, RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide